, Clinical Research Department Centre François Baclesse, Caen, France. 4 Medical Oncology Department, Centre François Baclesse, 14076 Caen, France. 5 Neurosurgery Department, Radiation Oncology Department, issue.3, 14000.

D. N. Louis, A. Perry, G. Reifenberger, A. Von-deimling, D. Figarella-branger et al., The 2016 World Health Organization classification of tumors of the central nervous system: a summary, Acta Neuropathol (Berl), vol.131, pp.803-823, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-96, 2005.

G. Minniti, D. Amelio, M. Amichetti, M. Salvati, R. Muni et al., Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.97, pp.377-81, 2010.

Y. Liu, Y. Shen, T. Sun, and W. Yang, Mechanisms regulating radiosensitivity of glioma stem cells, 2017.

S. U. Ahmed, R. Carruthers, L. Gilmour, S. Yildirim, C. Watts et al., Selective inhibition of parallel DNA damage response pathways optimizes Radiosensitization of glioblastoma stem-like cells, Cancer Res, vol.75, pp.4416-4444, 2015.

E. R. Laws, I. F. Parney, W. Huang, F. Anderson, A. M. Morris et al., Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project, J Neurosurg, vol.99, pp.467-73, 2003.

J. R. Simpson, J. Horton, C. Scott, W. J. Curran, P. Rubin et al., Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive radiation therapy oncology group (RTOG) clinical trials, Int J Radiat Oncol Biol Phys, vol.26, pp.239-283, 1993.

M. Lacroix, D. Abi-said, D. R. Fourney, Z. L. Gokaslan, W. Shi et al., A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival, J Neurosurg, vol.95, pp.190-198, 2001.

C. Beck, I. Robert, B. Reina-san-martin, V. Schreiber, F. Dantzer et al., ADPribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3, vol.329, pp.18-25, 2014.

R. Plummer, C. Jones, M. Middleton, R. Wilson, J. Evans et al., Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors, Clin Cancer Res Off J Am Assoc Cancer Res, vol.14, pp.7917-7940, 2008.

P. Lesueur, F. Chevalier, J. Austry, W. Waissi, H. Burckel et al., ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies, Oncotarget, vol.8, pp.69105-69129, 2017.
URL : https://hal.archives-ouvertes.fr/cea-01938036

H. E. Bryant, N. Schultz, H. D. Thomas, K. M. Parker, D. Flower et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADPribose) polymerase, Nature, vol.434, pp.913-920, 2005.

H. Farmer, N. Mccabe, C. J. Lord, A. Tutt, D. A. Johnson et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, pp.917-938, 2005.

F. A. Dungey, D. A. Löser, and A. J. Chalmers, Replication-dependent radiosensitization of human glioma cells by inhibition of poly (ADP-ribose) polymerase: mechanisms and therapeutic potential, Int J Radiat Oncol Biol Phys, vol.72, pp.1188-97, 2008.

, Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data. | 2013 ASCO Annual Meeting | Virtual Meeting | Meeting Library, 2017.

P. Lesueur, F. Chevalier, E. A. El-habr, M. Junier, H. Chneiweiss et al., Radiosensitization effect of Talazoparib, a Parp inhibitor, on glioblastoma Lesueur et al. BMC Cancer (2019) 19:198 stem cells exposed to low and high linear energy transfer radiation, Sci Rep, vol.8, p.3664, 2018.

S. Halford, G. Cruickshank, L. Dunn, S. Erridge, L. Godfrey et al., Results of the OPARATIC trial: a phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM), J Clin Oncol, vol.35, p.2022, 2017.

A. J. Chalmers, S. Short, C. Watts, C. Herbert, A. Morris et al., Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2, J Clin Oncol, vol.36, 2018.

L. D. Case and T. M. Morgan, Design of Phase II cancer trials evaluating survival probabilities, BMC Med Res Methodol, vol.3, p.6, 2003.

R. Stupp, P. Dietrich, O. Kraljevic, S. Pica, A. Maillard et al., Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide, J Clin Oncol Off J Am Soc Clin Oncol, vol.20, pp.1375-82, 2002.

B. Huang and P. F. Kuan, Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial, Biom J Biom Z, vol.56, pp.933-979, 2014.

N. A. Wages, M. R. Conaway, O. Quigley, and J. , Using the time-to-event continual reassessment method in the presence of partial orders, Stat Med, vol.32, pp.131-172, 2013.

P. Y. Wen, D. R. Macdonald, D. A. Reardon, T. F. Cloughesy, A. G. Sorensen et al., Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, pp.1963-72, 2010.